芬兰全国队列研究:单相抑郁药物治疗与再入院风险
结果显示锂盐使用与再入院风险降低相关,而抗抑郁药和抗精神病药未显示降低风险;单用锂盐风险低于锂盐联用抗抑郁药。
要点
- 锂盐使用与精神疾病再入院风险降低相关,单用锂盐风险低于联用抗抑郁药。
- 抗抑郁药和抗精神病药整体未显示降低再入院风险。
- 敏感性分析中所有药物再入院率均低于主分析,但效果排序一致。
核心结论
- 锂盐尤其是无联用抗抑郁药时,与严重单相抑郁患者精神疾病再入院风险最低相关。
- 抗抑郁药和抗精神病药在降低再入院风险方面劣于锂盐。
研究设计与样本
- 全国队列研究纳入芬兰1987年1月1日至2012年12月31日间至少一次因单相抑郁住院的患者,随访1996-2012年再入院风险。
- 主要分析为个体内分析,以个体自身对照消除选择偏倚;采用PRE2DUP法确定药物暴露与非暴露期。
临床怎么用
- 对严重单相抑郁患者,可考虑扩大锂盐适用范围,但需权衡其潜在风险与副作用。
- 临床决策中应关注锂盐单用与联用抗抑郁药在再入院风险上的差异。
局限性
- 观察性队列设计可能存在残余混杂。
- 敏感性分析控制生存偏倚和原发病偏倚后,所有药物再入院率均低于主分析,提示主分析可能受偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the comparative effectiveness of long-term pharmacological treatments for severe unipolar depression. We aimed to study the effectiveness of pharmacological treatments in relapse prevention in a nationwide cohort of patients who had been admitted to hospital at least once as a result of unipolar depression. METHODS: Our nationwide cohort study investigated the risk of readmission to hospital in 1996-2012 in all patients in Finland who had been admitted to hospital at least once for unipolar depression (without a diagnosis of schizophrenia or bipolar disorder) in Finland between Jan 1, 1987, and Dec 31, 2012. We used nationwide databases to obtain data for hospital admission, mortality, and dispensed medications. Exposure and non-exposure periods for medications were established using the PRE2DUP method. The primary analysis was within-individual analysis of readmission to hospital in the total cohort, in which each individual was used as his or her own control to eliminate selection bias. Putative survival and protopathic biases were controlled in sensitivity analyses. Since 33 independent statistical comparisons were done for specific medications, the level of statistical significance was set at p<0·0015. FINDINGS: Data from 123 712 patients were included in the total cohort, with a mean follow-up time of 7·9 years (SD 5·3). Lithium use was associated with a lower risk of re-admission to hospital for mental illness than was no lithium use (hazard ratio [HR] 0·47 [95% CI 0·40-0·55]; p<0·0001), whereas the groups of antidepressants (HR 1·10 [1·06-1·13]; p<0·0001) and antipsychotics (HR 1·16 [1·12-1·20]; p<0·0001) were not associated with a reduced risk of readmission to hospital. Risk of hospital readmission was lower during lithium therapy alone (HR 0·31 [0·21-0·47]; p<0·0001) than during use of lithium with antidepressants (HR 0·50 [0·43-0·59]; p<0·0001). After lithium, clozapine (HR 0·65 [0·46-0·90]; p=0·010) and amitriptyline (HR 0·75 [0·70-0·81]; p<0·0001) were the specific agents associated with the next lowest risk of readmission. In the sensitivity analyses controlling for survival and protopathic biases, all drugs were associated with lower rates of readmission to hospital than they were in the primary analysis, showing the same rank order in comparative effectiveness. The lowest mortality was observed during antidepressant use (HR 0·56 [0·54-0·58]; p<0·0001). INTERPRETATION: Our results indicate that lithium, especially without concomitant antidepressant use, is the pharmacological treatment associated with the lowest risk of hospital readmission for mental illness in patients with severe unipolar depression, and the outcomes for this measure related to antidepressants and antipsychotics are poorer than lithium. Lithium treatment should be considered for a wider population of severely depressed patients than those currently considered, taking into account its potential risks and side-effects. FUNDING: The Finnish Ministry of Health.
引用
- Tiihonen J, Tanskanen A, Hoti F, et al. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry. 2017. PMID: 28578901. doi:10.1016/S2215-0366(17)30134-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。